Klas Gosta Wiman
Corporate Officer/Principal bij Karolinska Institutet
Actieve functies van Klas Gosta Wiman
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | 15-05-2009 | - |
Loopbaan van Klas Gosta Wiman
Eerdere bekende functies van Klas Gosta Wiman
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
APREA THERAPEUTICS, INC. | Oprichter | 01-01-2002 | - |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Directeur/Bestuurslid | 01-01-2003 | - |
Oprichter | 01-01-2003 | - |
Statistieken
Internationaal
Zweden | 3 |
Verenigde Staten | 2 |
Operationeel
Founder | 2 |
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
APREA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Beurs
- Insiders
- Klas Gosta Wiman
- Ervaring